A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL001 in Patients With Advanced or Metastatic Solid Tumors
Latest Information Update: 17 May 2024
At a glance
- Drugs FTL 001 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Sound Biopharmaceuticals
Most Recent Events
- 17 May 2024 New trial record